Anika Therapeutics, Inc. (ANIK)

Over the past six months, Anika Therapeutics' stock has fluctuated, with a 52-week high of $18.35-$18.37 and a low of $7.87-$7.94; as of early February 2026, it was trading around $10.30-$10.46. Key events include Q3 and Q2 2025 earnings reports with negative EPS, a CEO transition and governance changes on January 8, 2026, a significant increase in short interest by 22.66% in early February 2026, and multiple investor alerts and investigations by law firms regarding potential claims. While the company posted a 17% increase in revenue in the last year, its revenue has fallen 24% over the past three years, and analysts predict a further decline of 0.5% over the next year.

Specific information regarding the demand seasonality for Anika Therapeutics' products and services is not available.

Anika Therapeutics, Inc. is a global joint preservation company focused on early intervention orthopedic care, operating in the Health Technology sector, specifically Medical Specialties, with a focus on orthobiologics and medical devices. Their products utilize a hyaluronic acid (HA) technology platform. Major products include HA-based viscosupplements for osteoarthritis pain management, orthopedic regenerative solutions, sports medicine solutions, and joint preservation solutions. They also offer HA-based products for veterinary use, anti-adhesion barriers, and treatments for burns, ulcers, ENT disorders, and ophthalmology.

Anika Therapeutics has a global presence with subsidiaries and distributors in North America, Europe, and Asia Pacific. The majority of its revenue comes from the United States, with a significant presence in Europe and other international markets.

Specific information detailing Anika Therapeutics' brand reputation is not readily available. However, ongoing investigations by law firms regarding potential securities fraud claims could negatively impact the company's reputation.

Institutional investors hold a significant portion of Anika Therapeutics' shares, owning approximately 65% to 84.82% of the company, with the top 10 shareholders collectively owning over 50%. Major institutional owners include BlackRock, Inc., Trigran Investments, Inc., Caligan Partners LP, Vanguard Group Inc., Acadian Asset Management Llc, Dimensional Fund Advisors Lp, Capital Management Corp /Va, Boothbay Fund Management, Llc, and Renaissance Technologies Llc. Farmaceutici Spa Fidia is the largest individual shareholder. Insider activity over the last 12 months indicates net selling.